Peninsula drug maker Cytokinetics ends late-stage study in ALS
Cytokinetics Inc. is discontinuing its late-stage study of a drug aimed at amyotrophic lateral sclerosis, the potentially deadly neuromuscular condition commonly known as Lou Gehrig's Disease. The South San Francisco company (NASDAQ: CYTK) said Friday a data monitoring committee recommended the Phase III clinical trial of the drug reldesemtiv be stopped after finding no evidence of effect in patients relative to placebo on improving a disease scale over 24 weeks. Cytokinetics' stock was up $1.09 per share, or more than 3%, to $35.30 in Friday morning trading.